| scholarly article | Q13442814 |
| P50 | author | Vladimír Dbalý | Q18193655 |
| Bernhard Ryffel | Q40398470 | ||
| Jean F Soustiel | Q118867697 | ||
| P2093 | author name string | Aviran Itzhaki | |
| Eilon D Kirson | |||
| Yoram Palti | |||
| Erez Dekel | |||
| Josef Vymazal | |||
| Marc Salzberg | |||
| Dorit Goldsher | |||
| Yoram Wasserman | |||
| Rosa Schneiderman | |||
| Daniel Mordechovich | |||
| Zoya Gurvich | |||
| Frantisek Tovarys | |||
| Shirley Steinberg-Shapira | |||
| P2860 | cites work | Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse | Q30647642 |
| Temozolomide in the treatment of recurrent malignant glioma | Q30890927 | ||
| Electrorotation and dielectrophoresis | Q33830544 | ||
| Disruption of cancer cell replication by alternating electric fields | Q34318661 | ||
| Alignment of microscopic particles in electric fields and its biological implications | Q34535596 | ||
| Ca(2+)-dependent mechanisms of cytotoxicity and programmed cell death | Q35237092 | ||
| Harnessing dielectric forces for separations of cells, fine particles and macromolecules | Q36204346 | ||
| A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse | Q36621800 | ||
| Contact dermatitis in hospital patients | Q38141434 | ||
| The development and application of pulsed electromagnetic fields (PEMFs) for ununited fractures and arthrodeses | Q39817876 | ||
| Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials | Q40789890 | ||
| Characterization of electric field-induced fusion in erythrocyte ghost membranes | Q41471949 | ||
| Studies of Thermal Injury: II. The Relative Importance of Time and Surface Temperature in the Causation of Cutaneous Burns. | Q42228402 | ||
| Comparison of iodotyrosines and methionine uptake in a rat glioma model | Q42461311 | ||
| Electrorotation of colloidal particles and cells depends on surface charge | Q42928979 | ||
| Phase II trial of gefitinib in recurrent glioblastoma | Q44669178 | ||
| Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 | ||
| Dielectrophoretic manipulation of macromolecules: the electric field. | Q46034972 | ||
| Morphometrical characterization of two glioma models in the brain of immunocompetent and immunodeficient rats | Q48192150 | ||
| Characterization of the Pore Transport Properties and Tissue Alteration of Excised Human Skin during Iontophoresis | Q54388930 | ||
| The Distribution of Radiofrequency Current and Burns | Q69473581 | ||
| Transmembrane calcium influx induced by ac electric fields | Q74645156 | ||
| Stimulation of muscles and nerves by means of externally applied electrodes | Q76493060 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain | Q1073 |
| brain tumor | Q233309 | ||
| P304 | page(s) | 10152-7 | |
| P577 | publication date | 2007-06-12 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors | |
| P478 | volume | 104 |
| Q92011777 | 5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon Cancer Therapy |
| Q90242240 | A 60 Hz uniform electromagnetic field promotes human cell proliferation by decreasing intracellular reactive oxygen species levels |
| Q33832747 | A Novel Micro Cold Atmospheric Plasma Device for Glioblastoma Both In Vitro and In Vivo |
| Q34304603 | A novel miniature dynamic microfluidic cell culture platform using electro-osmosis diode pumping |
| Q31130812 | A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma |
| Q51143849 | A supramolecular fluorescent vesicle based on a coordinating aggregation induced emission amphiphile: insight into the role of electrical charge in cancer cell division. |
| Q36379218 | A three-dimensional in vitro tumor platform for modeling therapeutic irreversible electroporation |
| Q48484929 | A toy model of fractal glioma development under RF electric field treatment |
| Q57809709 | AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields) |
| Q37796682 | Advanced dynamic monitoring of cellular status using label-free and non-invasive cell-based sensing technology for the prediction of anticancer drug efficacy |
| Q37256733 | Advancing practical usage of microtechnology: a study of the functional consequences of dielectrophoresis on neural stem cells |
| Q61813177 | Alternating Electric Fields (TTFields) Activate Ca1.2 Channels in Human Glioblastoma Cells |
| Q37394107 | Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo |
| Q37418672 | Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs |
| Q48281844 | Alternating electric fields and carcinogenesis: a new paradigm to avoid missing the elephant in the room |
| Q38905432 | Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. |
| Q47276703 | Amino Acid PET Imaging of the Early Metabolic Response During Tumor-Treating Fields (TTFields) Therapy in Recurrent Glioblastoma. |
| Q37166421 | Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach |
| Q26852232 | An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas |
| Q26770399 | An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma |
| Q28067498 | An Overview of Sub-Cellular Mechanisms Involved in the Action of TTFields. |
| Q42116930 | Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma. |
| Q37564404 | Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by noninvasive radiofrequency field treatment |
| Q89701782 | Barium Titanate Nanoparticles Sensitise Treatment-Resistant Breast Cancer Cells to the Antitumor Action of Tumour-Treating Fields |
| Q38074468 | Bioelectromagnetic medicine: the role of resonance signaling |
| Q38828969 | Biological activity of tumor-treating fields in preclinical glioma models |
| Q37641759 | Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation |
| Q39790372 | Biophysical cancer transformation pathway |
| Q51798614 | Biophysical insights into cancer transformation and treatment. |
| Q97645032 | CCL2 and IL18 expressions may associate with the anti-proliferative effect of noncontact electro capacitive cancer therapy in vivo |
| Q52599208 | Calculation of externally applied electric field intensity for disruption of cancer cell proliferation. |
| Q34634038 | Cancer cell proliferation is inhibited by specific modulation frequencies |
| Q33398646 | Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). |
| Q42129388 | Chronic inflammation: is it the driver or is it paving the road for malignant transformation? |
| Q47145292 | Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic compa |
| Q92049289 | Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial |
| Q49829484 | Commentary: Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy |
| Q92382773 | Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields |
| Q35891430 | Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme |
| Q94564001 | Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study |
| Q35285738 | Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3 Tesla |
| Q38122586 | Could radiotherapy effectiveness be enhanced by electromagnetic field treatment? |
| Q42361869 | Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields). |
| Q35863183 | Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma |
| Q35666016 | Differential Effects of Cold Atmospheric Plasma in the Treatment of Malignant Glioma |
| Q52571345 | Direct-Current Electric Field Distribution in the Brain for Tumor Treating Field Applications: A Simulation Study. |
| Q51733064 | Dosimetric Impact of a Tumor Treating Fields Device for Glioblastoma Patients Undergoing Simultaneous Radiation Therapy. |
| Q60303372 | EDEn-Electroceutical Design Environment: Ion Channel Tissue Expression Database with Small Molecule Modulators |
| Q47232913 | Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial |
| Q91892623 | Effectiveness of a Fractionated Therapy Scheme in Tumor Treating Fields Therapy |
| Q40000874 | Effects of radiation from a radiofrequency identification (RFID) microchip on human cancer cells |
| Q35505311 | Effects of substrate conductivity on cell morphogenesis and proliferation using tailored, atomic layer deposition-grown ZnO thin films |
| Q91419857 | Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition |
| Q37597681 | Electric field stimulation through a biodegradable polypyrrole-co-polycaprolactone substrate enhances neural cell growth |
| Q38022780 | Electric fields generated by synchronized oscillations of microtubules, centrosomes and chromosomes regulate the dynamics of mitosis and meiosis |
| Q39136205 | Electrical field manipulation of cancer cell behavior monitored by whole cell biosensing device |
| Q38070704 | Electrical methods of controlling bacterial adhesion and biofilm on device surfaces |
| Q27330267 | Electro-acoustic behavior of the mitotic spindle: a semi-classical coarse-grained model. |
| Q92716450 | Electromagnetic fields alter the motility of metastatic breast cancer cells |
| Q64105313 | Electrotaxis of Glioblastoma and Medulloblastoma Spheroidal Aggregates |
| Q90354272 | Emerging medical applications based on non-ionizing electromagnetic fields from 0 Hz to 10 THz |
| Q36928486 | Engineering a 3D microfluidic culture platform for tumor-treating field application |
| Q36151109 | Enhancing Predicted Efficacy of Tumor Treating Fields Therapy of Glioblastoma Using Targeted Surgical Craniectomy: A Computer Modeling Study |
| Q57168424 | Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients |
| Q47863423 | From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence |
| Q30383359 | Fröhlich's coherent excitations & the cancer problem--a retrospective overview of his guiding philosophy. |
| Q39546035 | Functionality of natural killer cells from end-stage cancer patients exposed to coherent electromagnetic fields. |
| Q30448586 | Fundamentals of transcranial electric and magnetic stimulation dose: definition, selection, and reporting practices |
| Q90926971 | Glioblastoma Therapy in the Age of Molecular Medicine |
| Q90618650 | Glioblastoma Treatment Modalities besides Surgery |
| Q57111067 | Glioblastoma Treatments: An Account of Recent Industrial Developments |
| Q38225874 | Glioblastoma multiforme: State of the art and future therapeutics |
| Q40030034 | Greater osteoblast proliferation on anodized nanotubular titanium upon electrical stimulation. |
| Q39377132 | Growth inhibition of malignant melanoma by intermediate frequency alternating electric fields, and the underlying mechanisms |
| Q48292017 | How treatment monitoring is influencing treatment decisions in glioblastomas |
| Q44327312 | Impact of mitochondrial electric field on modal occupancy in the Fröhlich model of cellular electromagnetism |
| Q36399129 | Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: A computer modeling study |
| Q57168103 | Importance of electrode position for the distribution of tumor treating fields (TTFields) in a human brain. Identification of effective layouts through systematic analysis of array positions for multiple tumor locations |
| Q38685276 | Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment |
| Q64959860 | Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. |
| Q41925185 | Individual differences in transcranial electrical stimulation current density |
| Q89777928 | Induction of apoptosis and ferroptosis by a tumor suppressing magnetic field through ROS-mediated DNA damage |
| Q48156660 | Industry progress report on neuro-oncology: a biotech update |
| Q35045999 | Influence of reactive species on the modification of biomolecules generated from the soft plasma. |
| Q92831964 | Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies |
| Q64946469 | Liquid Metal Enabled Electrobiology: A New Frontier to Tackle Disease Challenges. |
| Q42431574 | Living in a material world: tumor-treating fields at the top of the charts |
| Q34644506 | Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields |
| Q42635158 | Low-intensity alternating electric fields: a potentially safe and effective treatment of cancer? |
| Q47652837 | Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields |
| Q26740431 | Management of glioblastoma after recurrence: A changing paradigm |
| Q28078632 | Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology |
| Q42241395 | Microbial growth inhibition by alternating electric fields |
| Q34045228 | Microbial growth inhibition by alternating electric fields in mice with Pseudomonas aeruginosa lung infection |
| Q41281675 | Mild electrical stimulation at 0.1-ms pulse width induces p53 protein phosphorylation and G2 arrest in human epithelial cells. |
| Q30856517 | Mild electrical stimulation with heat shock ameliorates insulin resistance via enhanced insulin signaling |
| Q27303864 | Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells |
| Q37194638 | Murine model of neuromuscular electrical stimulation on squamous cell carcinoma: potential implications for dysphagia therapy. |
| Q64092850 | New electrical impedance methods for the in situ measurement of the complex permittivity of anisotropic skeletal muscle using multipolar needles |
| Q35700846 | Non-contact method for directing electrotaxis |
| Q98302984 | Non-thermal effects of radiofrequency electromagnetic fields |
| Q38978897 | Noninvasive radiofrequency treatment effect on mitochondria in pancreatic cancer cells |
| Q38019592 | NovoTTF-100A: a new treatment modality for recurrent glioblastoma |
| Q40329719 | NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study |
| Q49960924 | Optomechanical proposal for monitoring microtubule mechanical vibrations. |
| Q64104006 | Permittivity of ex vivo healthy and diseased murine skeletal muscle from 10 kHz to 1 MHz |
| Q91783609 | Physical energies to the rescue of damaged tissues |
| Q36181437 | Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement |
| Q33463289 | Plasma modification of poly(2-heptadecyl-4-vinylthieno[3,4-d]thiazole) low bandgap polymer and its application in solar cells |
| Q57153312 | Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma |
| Q53698488 | Pre-exposure to 50 Hz-electromagnetic fields enhanced the antiproliferative efficacy of 5-fluorouracil in breast cancer MCF-7 cells. |
| Q48260898 | Preclinical model of transcorneal alternating current stimulation in freely moving rats. |
| Q34063130 | Predicting the electric field distribution in the brain for the treatment of glioblastoma |
| Q98771134 | Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma |
| Q83911864 | Primary brain tumours in adults |
| Q39306583 | Radiofrequency currents exert cytotoxic effects in NB69 human neuroblastoma cells but not in peripheral blood mononuclear cells |
| Q64255530 | Rebound or Entrainment? The Influence of Alternating Current Stimulation on Individual Alpha |
| Q34438507 | Recurrent malignant gliomas |
| Q42204578 | Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma |
| Q41547378 | Response to Alternating Electric Fields of Tubulin Dimers and Microtubule Ensembles in Electrolytic Solutions. |
| Q114674406 | Retracted Article: Utility of plasma: a new road from physics to chemistry |
| Q57298076 | Selective toxicity of tumor treating fields to melanoma: an in vitro and in vivo study |
| Q38988000 | Silver nanoparticles increase cytotoxicity induced by intermediate frequency low voltages. |
| Q37525881 | Standards of care and novel approaches in the management of glioblastoma multiforme |
| Q34604804 | Strong synergy of heat and modulated electromagnetic field in tumor cell killing |
| Q52722815 | Study of the effects of 0.15 terahertz radiation on genome integrity of adult fibroblasts. |
| Q33584376 | TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters |
| Q42591781 | TTFields: where does all the skepticism come from? |
| Q36310547 | Targeted cellular ablation based on the morphology of malignant cells |
| Q34657282 | Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies |
| Q92446113 | Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma |
| Q38183215 | Technological developments and future perspectives on graphene-based metamaterials: a primer for neurosurgeons |
| Q43061847 | The Electrode Modality Development in Pulsed Electric Field Treatment Facilitates Biocellular Mechanism Study and Improves Cancer Ablation Efficacy. |
| Q38612761 | The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists |
| Q58919706 | The History of Hyperthermia Rise and Decline |
| Q39649965 | The control of neural cell-to-cell interactions through non-contact electrical field stimulation using graphene electrodes |
| Q33678976 | The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system |
| Q34348124 | The effects of non-invasive radiofrequency treatment and hyperthermia on malignant and nonmalignant cells |
| Q38730119 | The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells |
| Q36235790 | The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study. |
| Q35114090 | The future of high-grade glioma: Where we are and where are we going |
| Q58611807 | The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma |
| Q30452722 | Transcranial alternating current stimulation (tACS). |
| Q42742790 | Treating glioblastoma multiforme with electrical fields |
| Q48874224 | Treatment advances for glioblastoma |
| Q64243990 | Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review |
| Q57254086 | Treatment of recurrent high-grade gliomas |
| Q90211010 | Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis |
| Q37432387 | Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI. |
| Q92035246 | Tubulin response to intense nanosecond-scale electric field in molecular dynamics simulation |
| Q58720139 | Tubulin's response to external electric fields by molecular dynamics simulations |
| Q61806883 | Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune System |
| Q39406425 | Tumor Treating Fields in Neuro-Oncological Practice |
| Q90643198 | Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study |
| Q98179308 | Tumor Treating Fields in the Management of Patients with Malignant Gliomas |
| Q35970661 | Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma |
| Q47095665 | Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. |
| Q91210709 | Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy |
| Q59792020 | Tumor treating fields increases membrane permeability in glioblastoma cells |
| Q37662196 | Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis |
| Q27308744 | Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit |
| Q89534115 | Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial |
| Q38619307 | Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations |
| Q47852533 | Tumor treating fields: a new approach to glioblastoma therapy |
| Q34343822 | Tumor treating fields: a new frontier in cancer therapy |
| Q28073779 | Tumor treating fields: a novel treatment modality and its use in brain tumors |
| Q34183195 | Tumor treating fields: concept, evidence and future |
| Q89688131 | Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy |
| Q92550077 | Tumor-Treating Fields Induce RAW264.7 Macrophage Activation Via NK-κB/MAPK Signaling Pathways |
| Q90121638 | Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy |
| Q42292362 | Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines |
| Q92377636 | Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells |
| Q50920629 | Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. |
| Q90808642 | Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial |
| Q60050015 | Tumour treating fields in a combinational therapeutic approach |
| Q101216977 | Tumour treating fields therapy for glioblastoma: current advances and future directions |
| Q64056856 | Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis |
| Q55287222 | Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. |
| Q64325367 | Use of cold-atmospheric plasma in oncology: a concise systematic review |
| Q57804908 | Viral and other therapies for recurrent GBM: is a 24-month durable response unusual? |
| Q47899183 | Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? |
| Q55462049 | [Treatment of brain tumor patients: hyperthermia, hyperbaric oxygenation, electric fields or nanoparticles]. |
Search more.